Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
US11001628B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 27, 2016 |
| Grant date | May 11, 2021 |
| Priority date | — |
| Expiry date | Jul 27, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application n relates to a pharmaceutical composition comprising a PD-1 antibody and an M-CSF antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.